News
Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19
18 Apr 24
News, Price Target, Analyst Ratings
Oppenheimer Maintains Perform on Sage Therapeutics, Lowers Price Target to $17
18 Apr 24
News, Price Target, Analyst Ratings
In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics
18 Apr 24
Analyst Ratings
TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16
18 Apr 24
News, Price Target, Analyst Ratings
Needham Reiterates Hold on Sage Therapeutics
18 Apr 24
News, Reiteration, Analyst Ratings
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
17 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $28 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $24 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
17 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
17 Apr 24
Biotech, News, Health Care, Top Stories, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Apr 24
Movers
B of A Securities Downgrades Sage Therapeutics to Underperform, Lowers Price Target to $14
17 Apr 24
News, Downgrades, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
17 Apr 24
Movers
J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
17 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Sage Therapeutics Announces Topline Results From Phase 2 PRECEDENT Study Of Dalzanemdor (SAGE-718) In The Treatment Of Mild Cognitive Impairment In Parkinson's Disease
17 Apr 24
News
Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews
26 Mar 24
Analyst Ratings
RBC Capital Reiterates Sector Perform on Sage Therapeutics, Maintains $26 Price Target
11 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights
28 Feb 24
Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Raises Price Target to $22
28 Feb 24
News, Price Target, Analyst Ratings
Press releases
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease
17 Apr 24
Press Releases
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
11 Apr 24
Press Releases
Sage Therapeutics to Present at Upcoming March Investor Conferences
28 Feb 24
Press Releases
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
14 Feb 24
Press Releases
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
31 Jan 24
Press Releases